Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-Blind, randomized, placebo-controlled study

Table 2 Percent change from baseline to study visits in efficacy parameters

Variable		Statin + CoA (n = 152)	Mean percent change, % ± SE (median)	Statin + Placebo (n = 152)	Mean percent change, % ± SE (median)	p value
TG, mmol/L	Baseline	3.58 ± 1.26		3.42 ± 1.12
	Week 4	2.71 ± 1.70	-24.70 ± 37.69 (-32.69, range -228.83 ~ 90.91)	3.07 ± 1.93	-9.77 ± 48.32 (-16.59, range -245.79 ~ 81.82)	0.0029
	Week 8	2.69 ± 2.21	-25.86 ± 50.35 (-36.81, range -386.65 ~ 85.59)	3.23 ± 1.99	-4.87 ± 48.77 (-9.63, range -234.51 ~ 84.49)	0.0003
TC, mmol/L	Baseline	5.37 ± 1.17*		5.08 ± 1.22
	Week 4	4.84 ± 1.10	-8.22 ± 18.62 (-8.67)	4.78 ± 1.21	-4.66 ± 17.16 (-4.12)	0.085
	Week 8	4.79 ± 1.07	-9.13 ± 18.95 (-9.43)	4.86 ± 1.25	-3.13 ± 16.16 (-3.21)	0.0033
HDL-C, mmol/L	Baseline	1.20 ± 0.31		1.15 ± 0.30
	Week 4	1.24 ± 0.33	6.17 ± 25.87 (1.59)	1.19 ± 0.32	4.86 ± 20.41 (0.00)	0.63
	Week 8	1.26 ± 0.36	7.92 ± 28.27 (1.84)	1.23 ± 0.38	8.16 ± 25.87 (1.91)	0.94
LDL-C, mmol/L	Baseline	2.91 ± 0.98		2.71 ± 0.92
	Week 4	2.61 ± 0.94	-6.35 ± 30.90 (-10.85)	2.57 ± 0.94	-2.51 ± 26.46 (-3.56)	0.25
	Week 8	2.53 ± 0.92	-9.90 ± 29.73 (-12.21)	2.63 ± 0.90	0.10 ± 28.28 (-1.46)	0.003
non-HDL-C, mmol/L	Baseline	4.18 ± 1.10		3.92 ± 1.16
non-HDL-C, mmol/L	Week 4	3.60 ± 1.08	-11.64 ± 23.43 (-13.79)	3.59 ± 1.17	-6.61 ± 22.97 (-6.41)	0.06
	Week 8	3.53 ± 1.06	-13.45 ± 24.02 (-15.39)	3.64 ± 1.21	-5.73 ± 22.14 (-5.28)	0.0039

All values are mean ± standard deviation (SD) unless otherwise specified.
Note: CoA = coenzyme A; TG = triglyceride; TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol. p values indicate the percent change between the two groups. *p = 0.034, between-group comparison of baseline TC level.

ISSN: 1476-511X